This is it. Great news."This randomized, placebo controlled, double blind clinical trial is expected to enroll 100 patients and will not only evaluate critical biomarkers and incidence of ARIA but will also extend for 12 months to enable us to measure important clinical endpoints. "
Basically getting to some Phase 2 type milestones during phase 1... and getting a robust ARIA data set.
I think the the PR was well written. Warma is doing great. Differentiating us from the rest of the market- well done.
Now if only the pps would reflect these great developments! All in good time. I'll be buying again soon.